Aadi Bioscience Inc (AADI) Stock: What Does the Chart Say Friday?

Aadi Bioscience Inc (AADI) stock has risen 20.24% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Aadi Bioscience Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AADI!

See Full AADI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With AADI Stock Today?

Aadi Bioscience Inc (AADI) stock has risen 6.05% while the S&P 500 is lower by -0.36% as of 10:56 AM on Friday, Aug 25. AADI is up $0.40 from the previous closing price of $6.61 on volume of 73,393 shares. Over the past year the S&P 500 has risen 5.31% while AADI is lower by -49.09%. AADI lost -$2.43 per share in the over the last 12 months. To screen for more stocks like Aadi Bioscience Inc click here.

More About Aadi Bioscience Inc

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Click Here to get the full Stock Report for Aadi Bioscience Inc stock.